share_log

HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target

Benzinga ·  Apr 5, 2023 18:50

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment